Publisher: Manufactured by: Hansel Pharmaceuticals (Pvt.) Ltd., Plot No.2, Pharma City, 30 Km. Multan Road, Sundar, Lahore Pakistan Under Licence of: CHIESI FARMACEUTICI S.p.A. - 26/A,Via Palermo PARMA, ITALY ...
BAMIFIX contains bamifylline, a methylxanthinic derivative with two side chains in position 7 and 8, distinguishing it clearly from theophylline.
Bamifylline carries out a bronchospasmolytic action on the smooth musculature and also blocks the action of the bronchoconstriction mediators.
The intensity of its bronchospasmolytic action is equal to that of theophylline.
Unlike theophylline, bamifylline usually has no exciting effects on the central nervous system.
Its pharmacokinetic characteristics are very interesting. Its absorption, both by oral and rectal route, is rapid, reaching the plasma peak between the first and the second hour. Its diffusion in the extravascular area is high, with a distribution volume equal to 1000 liters.
Bamifylline is rapidly metabolized to give 3 metabolites, also active and marked by high plasma concentrations. The prolonged activity of the drug allows for two daily administrations only.
Bamifylline final elimination half-life is of 17.5 hours. The excretion mostly occurs by urinary route.
Bamifylline shows a high therapeutical index, due to the wide interval between the minimum active and the maximum tolerated plasma levels (0.18 and 20 ug/ml, respectively).
The twice-daily administration of bamifylline leads to plasma levels of steady-state within 3-5 days both for bamifylline and its metabolites.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
